What is HC Wainwright's Forecast for ARTV Q3 Earnings?

Key Points

• HC Wainwright lowered its Q3 2026 EPS estimate for Artiva Biotherapeutics to a loss of $0.54 per share from $0.50, while maintaining a “Buy” rating and a $35 price target.
• Artiva reported a Q2 loss of $0.63 per share, matching consensus estimates. HC Wainwright projects continued losses through 2029 before forecasting positive EPS of $0.22 in 2030.
• Analyst sentiment remains generally favorable, with a MarketBeat consensus rating of “Moderate Buy” and an average price target of $39, despite one sell rating.

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) - Equities research analysts at HC Wainwright decreased their Q3 2026 EPS estimates for Artiva Biotherapeutics in a research report issued on Friday, August 7th. HC Wainwright analyst E. Bodnar now expects that the company will earn ($0.54) per share for the quarter, down from their prior estimate of ($0.50). HC Wainwright currently has a "Buy" rating and a $35.00 target price on the stock. The consensus estimate for Artiva Biotherapeutics' current full-year earnings is ($2.45) per share. HC Wainwright also issued estimates for Artiva Biotherapeutics' Q4 2026 earnings at ($0.65) EPS, FY2026 earnings at ($2.63) EPS, FY2027 earnings at ($3.31) EPS, FY2028 earnings at ($4.00) EPS, FY2029 earnings at ($2.17) EPS and FY2030 earnings at $0.22 EPS.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.63) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.63).

A number of other analysts have also commented on ARTV. Wedbush lifted their price objective on Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an "outperform" rating in a research report on Monday, May 11th. Needham & Company LLC restated a "buy" rating and set a $41.00 target price on shares of Artiva Biotherapeutics in a research report on Monday, June 8th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Artiva Biotherapeutics in a research note on Tuesday, May 26th. Wall Street Zen upgraded shares of Artiva Biotherapeutics from a "sell" rating to a "hold" rating in a research report on Saturday. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Artiva Biotherapeutics in a research note on Tuesday, July 21st. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Artiva Biotherapeutics has an average rating of "Moderate Buy" and an average price target of $39.00.

Artiva Biotherapeutics Stock Performance

Shares of ARTV opened at $11.22 on Tuesday. Artiva Biotherapeutics has a 52 week low of $2.22 and a 52 week high of $14.53. The firm has a market capitalization of $277.36 million, a price-to-earnings ratio of -3.40 and a beta of 2.16. The business's fifty day moving average price is $9.43 and its two-hundred day moving average price is $7.81.

Insider Transactions at Artiva Biotherapeutics

In other news, CEO Fred Aslan sold 27,116 shares of the business's stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $9.01, for a total transaction of $244,315.16. Following the completion of the transaction, the chief executive officer directly owned 1,535,082 shares in the company, valued at approximately $13,831,088.82. The trade was a 1.74% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Ra Capital Management, L.P. purchased 548,580 shares of the business's stock in a transaction that occurred on Thursday, June 11th. The stock was purchased at an average price of $7.91 per share, for a total transaction of $4,339,267.80. Following the completion of the transaction, the director directly owned 16,231,717 shares in the company, valued at $128,392,881.47. This trade represents a 3.50% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders have acquired 1,965,251 shares of company stock worth $16,188,035 and have sold 53,040 shares worth $477,890. 1.80% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Artiva Biotherapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in ARTV. State of Wyoming acquired a new position in shares of Artiva Biotherapeutics in the 2nd quarter valued at $45,000. Bank of America Corp DE lifted its holdings in Artiva Biotherapeutics by 225.8% during the third quarter. Bank of America Corp DE now owns 16,145 shares of the company's stock worth $46,000 after acquiring an additional 11,190 shares in the last quarter. Prelude Capital Management LLC bought a new position in Artiva Biotherapeutics during the third quarter worth about $41,000. Dimensional Fund Advisors LP acquired a new position in Artiva Biotherapeutics in the first quarter valued at about $131,000. Finally, OMERS ADMINISTRATION Corp acquired a new position in Artiva Biotherapeutics in the fourth quarter valued at about $91,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company's proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva's pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source